Tuesday, January 26, 2021  | 11 Jamadilakhir, 1442
Samaa TV
Facebook Twitter Youtube
HOME > Health

Actemra trials begin on COVID-19 patients in Punjab

115 patients are registered for the study

SAMAA | - Posted: Jun 13, 2020 | Last Updated: 8 months ago
Posted: Jun 13, 2020 | Last Updated: 8 months ago
Actemra trials begin on COVID-19 patients in Punjab

Photo: Roche/ website

Clinical trials of the anti-inflammatory drug tocilizumab (Actemra) for COVID-19 have begun in selected public and private hospitals in Punjab.

Tocilizumab is immunosuppressive drug used for rheumatoid arthritis. It works by decreasing the severity of the immune response known as a cytokine storm.

This is what has been responsible for a great number of coronavirus deaths. Clinical trials of tocilizumab are taking place in different countries and have shown some degree of success.

In a government notification, Punjab’s Corona Experts Advisory Group (CEAG) listed the conditions that would apply to the hospitals taking part in the tocilizumab trials.

Only designated public sector hospitals are allowed to procure the Actemra injection, which will exclusively be used for the patients registered for the study.

The drug would only be given to severely ill COVID-19 patients admitted in the ICUs of these hospitals. These patients will be monitored separately from other admitted patients. Around 115 patients are enrolled in the trial.

M/S Roche and all designated hospitals are directed to ensure 24 hours service to supply injections. Roche will provide the medicine to private hospitals.

Meanwhile, the sale of injection in the market, including at medical stores and hospital pharmacies, is completely banned, according to the Punjab Specialised Healthcare and Medical Education Department.

There have been reports of shortage of the medicine in markets. While it has a market price of around Rs12,000, Actemra is also being sold in black for as much as Rs100,000-200,000, according to reports on the social media.

In public hospitals a provincial committee will monitor the study on the use of tocilizumab. It will be comprising the following:

  • Dr Javed Hayat Khan, pulmonologist PKLI Lahore
  • Professor Saqib Saeed, head of Department of Chest Diseases
  • Professor Kamran Cheema, head of the Pulmonology Department at SIMS Lahore
  • Dr Irfan Malik, associate professor pulmonology at AMC/LGH Lahore

The Punjab Healthcare Commission will be responsible for private hospitals.

In both sectors, doctors treating the patients will have to record themselves using video camera while opening the injection pack and administering the drug.

This video along with clinical records of the patients will be given to the respective committees.  

FaceBook WhatsApp

Tell us what you think:

Your email address will not be published.

FaceBook WhatsApp

coronavirus vaccine pakistan news today, coronavirus vaccine trials in pakistan, bcg vaccine pakistan coronavirus, astrazeneca covid vaccine approval, astrazeneca vaccine update, astrazeneca vaccine approval, astrazeneca covid vaccine efficacy, astrazeneca vaccine type, astrazeneca vaccine vs pfizer, astrazeneca vaccine usa, astrazeneca vaccine india, oxford university-astrazeneca covid-19 vaccine status, sinopharm vs pfizer, sinovac vaccine efficacy, sinovac vs pfizer vaccine

Lahore administration demolishes part of Khokhar Palace
Rawalpindi man hit by train while ‘filming TikTok’
COVID-19 vaccine updates in Pakistan and around the world
Pak Suzuki fails to deliver Cultus, Swift over supply issues
Filthy rich: A Karachi sewer operation for a sick city
NADRA to issue succession certificates in two weeks
Watch: Rana Sanaullah makes a roaring entry to Lahore court
Karachi braces for another cold wave, Siberian winds in city
Traffic plan for JUI-F’s anti-Israel march in Karachi
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp